Trial Profile

Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tandospirone (Primary)
Indications Generalised anxiety disorder
Focus Therapeutic Use
Acronyms TACGAD
Sponsors Sumitomo Dainippon Pharma; Sumitomo Pharma

Most Recent Events

01 Apr 2023 Results of post hoc analysis assessing arly outcomes, associated factors and predictive values of clinical outcomes of different tandospirone doses in patients with a generalized anxiety disorder published in the Current Medical Research and Opinion
05 Jan 2020 Status changed from recruiting to completed.
15 Apr 2019 Planned End Date changed from 1 Dec 2017 to 1 Jul 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com